HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Frederick L Locke Selected Research

B-Cell Lymphoma (Lymphoma, B Cell)

10/2022Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium.
7/2022Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma.
1/2022Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma.
1/2022Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States.
1/2022Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the US.
1/2022Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.
1/2022Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma.
12/2021CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma.
12/2021Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell Therapy.
10/2021Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Frederick L Locke Research Topics

Disease

31B-Cell Lymphoma (Lymphoma, B Cell)
10/2022 - 12/2017
18Neoplasms (Cancer)
01/2022 - 09/2013
14Lymphoma (Lymphomas)
10/2022 - 01/2017
11Cytokine Release Syndrome
10/2022 - 01/2017
10Graft vs Host Disease (Graft-Versus-Host Disease)
11/2022 - 12/2012
10Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)
06/2022 - 12/2017
7Hematologic Neoplasms (Hematological Malignancy)
06/2022 - 01/2017
5Mantle-Cell Lymphoma (Lymphoma, Mantle Cell)
06/2022 - 01/2020
4Bronchiolitis Obliterans Syndrome
11/2022 - 12/2012
4Multiple Myeloma
01/2021 - 01/2012
4B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
01/2018 - 10/2014
3Infections
01/2022 - 01/2021
3cell-associated neurotoxicity
12/2021 - 12/2020
3Disease Progression
01/2020 - 01/2015
3Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular)
01/2019 - 12/2017
2Neutropenia
01/2022 - 12/2021
2Inflammation (Inflammations)
12/2021 - 10/2020
2Body Weight (Weight, Body)
01/2020 - 12/2017
2Leukemia
01/2019 - 12/2017
1Residual Neoplasm
06/2022
1Fatigue
06/2022
1Pain (Aches)
06/2022
1Non-Hodgkin Lymphoma (Lymphosarcoma)
01/2022
1Pleural Effusion (Pleural Effusions)
01/2021
1Cytopenia
01/2021
1Cardiovascular Diseases (Cardiovascular Disease)
01/2020
1Brain Diseases (Brain Disorder)
01/2020
1Cardiotoxicity
12/2019
1Heart Failure
12/2019
1Abdominal Pain (Pain, Abdominal)
12/2019
1Aplastic Anemia (Anemia, Hypoplastic)
03/2017
1Seroma
07/2015
1Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma)
07/2015

Drug/Important Bio-Agent (IBA)

36Chimeric Antigen ReceptorsIBA
10/2022 - 01/2017
30axicabtagene ciloleucelIBA
10/2022 - 01/2017
8tisagenlecleucelIBA
12/2021 - 01/2020
3GlucocorticoidsIBA
11/2022 - 06/2015
3tocilizumab (atlizumab)FDA Link
01/2021 - 12/2019
3Tacrolimus (Prograf)FDA LinkGeneric
01/2021 - 12/2012
3AntigensIBA
01/2020 - 09/2013
2ofatumumabFDA Link
11/2022 - 06/2015
2brexucabtagene autoleucelIBA
06/2022 - 01/2020
2Adrenal Cortex Hormones (Corticosteroids)IBA
01/2022 - 01/2021
2Ferritins (Ferritin)IBA
12/2021 - 01/2021
2Cyclophosphamide (Cytoxan)FDA LinkGeneric
11/2021 - 12/2017
2Sirolimus (Rapamycin)FDA Link
07/2015 - 12/2012
2Methotrexate (Mexate)FDA LinkGeneric
07/2015 - 12/2012
1Prednisone (Sone)FDA LinkGeneric
11/2022
1FluoroquinolonesIBA
01/2022
1CytokinesIBA
12/2021
1Hemoglobins (Hemoglobin)IBA
12/2021
1Biomarkers (Surrogate Marker)IBA
12/2021
1C-Reactive ProteinIBA
12/2021
1Mycophenolic Acid (Cellcept)FDA LinkGeneric
01/2021
1Circulating Tumor DNAIBA
01/2021
1Histone Deacetylase InhibitorsIBA
01/2021
1SteroidsIBA
01/2021
1bis(3- bis(4- chlorophenyl)methyl- 4- dimethylaminophenyl)amineIBA
01/2021
1Interleukin-6 (Interleukin 6)IBA
01/2021
1Anti-Bacterial Agents (Antibiotics)IBA
01/2021
1InterferonsIBA
01/2021
1PanobinostatIBA
01/2021
1LigandsIBA
01/2021
1NivolumabIBA
11/2020
1Beclomethasone (Beclometasone)FDA Link
01/2020
1Budesonide (Pulmicort)FDA LinkGeneric
01/2020
1Agammaglobulinaemia Tyrosine KinaseIBA
01/2020
1TroponinIBA
12/2019
1AnthracyclinesIBA
01/2019
1obinutuzumabIBA
01/2019
1Monoclonal AntibodiesIBA
01/2019
1DNA (Deoxyribonucleic Acid)IBA
01/2018
1ibrutinibIBA
01/2018
1Viral DNAIBA
01/2018
1fludarabineIBA
12/2017
1Daclizumab (Zenapax)FDA Link
03/2017
1IceIBA
01/2017
1Lenalidomide (CC 5013)FDA Link
01/2016
1Rituximab (Mabthera)FDA Link
01/2016
1RNA (Ribonucleic Acid)IBA
07/2015
1SiliconesIBA
07/2015
1Anaplastic Lymphoma KinaseIBA
07/2015
1Keratins (Keratin)IBA
07/2015
1SurvivinIBA
01/2015
1Messenger RNA (mRNA)IBA
01/2015
1Peptides (Polypeptides)IBA
01/2015
1Proteins (Proteins, Gene)FDA Link
01/2015

Therapy/Procedure

41Therapeutics
11/2022 - 05/2007
12Cell Transplantation
07/2022 - 12/2012
9Drug Therapy (Chemotherapy)
01/2022 - 01/2019
7Immunotherapy
01/2022 - 09/2013
4Transplantation
11/2021 - 03/2017
3Homologous Transplantation
11/2021 - 01/2020
2Stem Cell Transplantation
01/2022 - 01/2019
2Cell- and Tissue-Based Therapy (Cell Therapy)
01/2017 - 09/2013
1Length of Stay
01/2021
1Drug Tapering
12/2019
1Radiotherapy
12/2019
1Bone Marrow Transplantation (Transplantation, Bone Marrow)
03/2017
1Breast Implants (Breast Implant)
07/2015